Stefan J Teipel1, Thomas Meindl, Lea Grinberg, Helmut Heinsen, Harald Hampel. 1. Dementia and Neuroimaging Section, Department of Psychiatry, Alzheimer Memorial Center, Ludwig-Maximilian University, Nussbaumstrasse 7, Munich, Germany. stefan.teipel@med.uni-muenchen.de
Abstract
INTRODUCTION: Positive markers of Alzheimer's disease (AD) have been established in MRI that may allow early detection of AD in at-risk groups. In the near future, these markers will be of high relevance for the selection of at-risk subjects in secondary preventive trials. METHODS: We describe the methodology and diagnostic value of manual volumetry of the hippocampus and entorhinal cortex, automated voxel-based morphometry, cortical thickness measurement, basal forebrain volumetry and deformation-based morphometry, implementing multivariate statistics and machine learning algorithms to improve group separation and prediction of AD in at-risk groups. We also describe the methodological basis and results obtained in AD using the recently developed technique of diffusion tensor-based morphometry (DTI). This technique gives access to the integrity of subcortical fibre systems in the human brain. RESULTS: The best established structural biomarker of AD to date is hippocampus volume that already has been implemented as secondary endpoint in clinical trials on disease modification in AD. Automated approaches will gain an increasing role as endpoints of clinical trials in the near future given the interest in these techniques expressed by the regulatory authorities. DTI is still a developing field where analysis techniques are presently being devised to make optimal use of the multivariate data. Data on changes of fibre tract in preclinical AD are still limited, but the first results are promising in respect to a further enhancement of diagnostic accuracy by combining MRI and DTI. CONCLUSION: Besides their diagnostic use, MRI and DTI will broaden our understanding of the pathophysiology of AD and the structural and functional basis of normal cognition.
INTRODUCTION: Positive markers of Alzheimer's disease (AD) have been established in MRI that may allow early detection of AD in at-risk groups. In the near future, these markers will be of high relevance for the selection of at-risk subjects in secondary preventive trials. METHODS: We describe the methodology and diagnostic value of manual volumetry of the hippocampus and entorhinal cortex, automated voxel-based morphometry, cortical thickness measurement, basal forebrain volumetry and deformation-based morphometry, implementing multivariate statistics and machine learning algorithms to improve group separation and prediction of AD in at-risk groups. We also describe the methodological basis and results obtained in AD using the recently developed technique of diffusion tensor-based morphometry (DTI). This technique gives access to the integrity of subcortical fibre systems in the human brain. RESULTS: The best established structural biomarker of AD to date is hippocampus volume that already has been implemented as secondary endpoint in clinical trials on disease modification in AD. Automated approaches will gain an increasing role as endpoints of clinical trials in the near future given the interest in these techniques expressed by the regulatory authorities. DTI is still a developing field where analysis techniques are presently being devised to make optimal use of the multivariate data. Data on changes of fibre tract in preclinical AD are still limited, but the first results are promising in respect to a further enhancement of diagnostic accuracy by combining MRI and DTI. CONCLUSION: Besides their diagnostic use, MRI and DTI will broaden our understanding of the pathophysiology of AD and the structural and functional basis of normal cognition.
Authors: D P Devanand; G Pradhaban; X Liu; A Khandji; S De Santi; S Segal; H Rusinek; G H Pelton; L S Honig; R Mayeux; Y Stern; M H Tabert; M J de Leon Journal: Neurology Date: 2007-03-13 Impact factor: 9.910
Authors: Andreas Fellgiebel; Matthias J Müller; Paulo Wille; Paulo R Dellani; Armin Scheurich; Lutz G Schmidt; Peter Stoeter Journal: Neurobiol Aging Date: 2005-01-12 Impact factor: 4.673
Authors: Stefan J Teipel; Christine Born; Michael Ewers; Arun L W Bokde; Maximilian F Reiser; Hans-Jürgen Möller; Harald Hampel Journal: Neuroimage Date: 2007-07-18 Impact factor: 6.556
Authors: Michelle M Mielke; Ozioma C Okonkwo; Kenichi Oishi; Susumu Mori; Sarah Tighe; Michael I Miller; Can Ceritoglu; Timothy Brown; Marilyn Albert; Constantine G Lyketsos Journal: Alzheimers Dement Date: 2012 Impact factor: 21.566
Authors: Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow Journal: Nat Rev Drug Discov Date: 2010-07 Impact factor: 84.694
Authors: Jeffrey Dewey; George Hana; Troy Russell; Jared Price; Daniel McCaffrey; Jaroslaw Harezlak; Ekta Sem; Joy C Anyanwu; Charles R Guttmann; Bradford Navia; Ronald Cohen; David F Tate Journal: Neuroimage Date: 2010-03-22 Impact factor: 6.556
Authors: Kay Jann; Andrea Federspiel; Stéphanie Giezendanner; Jennifer Andreotti; Mara Kottlow; Thomas Dierks; Thomas Koenig Journal: Brain Connect Date: 2012
Authors: Y Likitjaroen; T Meindl; U Friese; M Wagner; K Buerger; H Hampel; S J Teipel Journal: Eur Arch Psychiatry Clin Neurosci Date: 2011-08-05 Impact factor: 5.270
Authors: Stefan J Teipel; Thomas Meindl; Lea Grinberg; Michel Grothe; Jose L Cantero; Maximilian F Reiser; Hans-Jürgen Möller; Helmut Heinsen; Harald Hampel Journal: Hum Brain Mapp Date: 2010-07-29 Impact factor: 5.038